BIODEXA PHARMACEUTICALS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.022 USD | +2.15% |
|
-22.61% | -61.88% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 3.529 | 5.515 | 3.496 | - | - |
| Enterprise Value (EV) 1 | 3.529 | 5.515 | 3.496 | 3.496 | 3.496 |
| P/E ratio | -2.1 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 14.5 x | - | - | - |
| EV / Revenue | - | 14.5 x | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -0.32 x | -0.22 x | -0.17 x |
| FCF Yield | - | - | -315% | -458% | -601% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13.5 | 2,620 | 4,385 | - | - |
| Reference price 2 | 260.6 | 2.105 | 0.7973 | 0.7973 | 0.7973 |
| Announcement Date | 4/28/23 | 4/19/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 0.381 | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -8.014 | -12.66 | -16.95 | -22.74 |
| Operating Margin | - | -2,103.41% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -7.656 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | -124.0 | - | - | - | - |
| Free Cash Flow 1 | - | - | -11 | -16 | -21 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/28/23 | 4/19/24 | - | - | - |
1GBP in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|
| Net sales 1 | 0.298 | 0.083 | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -3.77 | -5.617 | -7.038 |
| Operating Margin | - | -4,542.17% | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | -3.568 | - | - | - |
| Net margin | -1,197.32% | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 9/29/23 | 4/19/24 | - | - |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -11 | -16 | -21 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.01 | 0.05 | 0.11 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/28/23 | 4/19/24 | - | - | - |
1GBP in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7973
GBP
Average target price
6.337
GBP
Spread / Average Target
+694.82%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -61.88% | 4.38M | |
| +3.62% | 106B | |
| +7.02% | 23.47B | |
| -14.76% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -10.00% | 16.78B | |
| +5.70% | 14.41B | |
| +34.99% | 12.86B | |
| +321.28% | 8.78B |
- Stock Market
- Equities
- BDRX Stock
- Financials Biodexa Pharmaceuticals Plc